NCT01933880
A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants
See it on ClinicalTrials.gov ↗168 people
22%
78%
37 womenmiddle line = equal numbers131 men
- Phase
- PHASE4
- Paid for by
- Xian-Janssen Pharmaceutical Ltd.
- Finished
- 2010-11
- Health conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Who could join
- Anyone
- Ages
- 7 Years – 12 Years
- Average age
- Not reported
- Age 65+
- 0%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- Age limit under 65
Older women were turned away, even though they often take this medicine.
“Maximum age: 12 Years.”
- No mental health conditions
Women with depression, bipolar disorder or other mental health conditions were turned away.
“Have medical history of type I or II bipolar affective disorder, anxiety disorder, schizophrenia or pervasive developmental disorder”
Study titles and rules are shown in their original English.